Contributions to sofosbuvir

edit

Schinazi's contribution to the discovery of sofosbuvir is contentious. He is the co-author of a 2005 paper that discovered a precursor to the drug.[1] Jean-Pierre Sommadossi, a principal founder of Idenix and a co-founder of Pharmasset, has stated that Schinazi “wasn't involved with anything” in the actual development of sofosbuvir. Schinazi's former business partner no longer speaks to him.[1][2]

Previous material violates Wikipedia Policy. The point of view was not neutral and the statements are not well sourced. One statement is merely opinion. Selected fragments of source material have been taken and are presented in a contentious manner to disparage. Other non-disparaging source material was not provided.

References

  1. ^ a b Cite error: The named reference :0 was invoked but never defined (see the help page).
  2. ^ "Gilead's Patent Loss to Merck Started With a Broken Friendship". {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)